NEUROD1-driven SCLC (SCLC-N) accounts for ~15% of SCLC cases and is characterized by high NEUROD1 expression, often co-expressed with MYC, which drives rapid tumor proliferation [14,23]. Here, MYC is linked to neoplasm.